PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29731965-10	2018	In this study, the presence of both TP53 mutation and 17p/TP53 deletion, but not the individual variants, was associated with poor prognosis in DLBCL patients after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or similar regimens.	Prednisone	238-248	tumor protein p53	Homo sapiens	36-40	
7563172-0	1995	Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.	Prednisone	156-166	tumor protein p53	Homo sapiens	16-19	
29731965-10	2018	In this study, the presence of both TP53 mutation and 17p/TP53 deletion, but not the individual variants, was associated with poor prognosis in DLBCL patients after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or similar regimens.	Prednisone	238-248	tumor protein p53	Homo sapiens	58-62	
20435884-3	2010	Losses of TP53 and CDKN2A, observed in 8% and 35% of patients, respectively, were significantly associated with a shorter survival after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment, independently of the International Prognostic Index and of the cell of origin.	Prednisone	196-206	tumor protein p53	Homo sapiens	10-14	
22955915-1	2012	TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy.	Prednisone	181-191	tumor protein p53	Homo sapiens	0-4	
28791403-10	2017	Among DLBCL cases, the TP53 mutations shortened both OS and PFS of patients treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) and decreased both OS and PFS of patients with secondary DLBCL disease.	Prednisone	155-165	tumor protein p53	Homo sapiens	23-27	
21290342-0	2010	Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia.	Prednisone	92-102	tumor protein p53	Homo sapiens	27-30	
21290342-2	2010	p53 plays a crucial role in triggering apoptosis of ALL in response to prednisone treatment.	Prednisone	71-81	tumor protein p53	Homo sapiens	0-3	
21290342-4	2010	This study is aimed to evaluate changes in MDM2 and p53 expression in peripheral blood mononuclear cells collected from children with ALL prior to and after 6 and 12 h of prednisone administration in relation to early treatment response.	Prednisone	171-181	tumor protein p53	Homo sapiens	52-55